InventisBio Co. Ltd. A (688382.SS) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · China · ISIN CNE100005Q22
InventisBio Co. Ltd. A financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 168.79 m CNY | 37.29 m CNY |
| Gross profit | 164.87 m CNY | 32.27 m CNY |
| Operating income | -263.51 m CNY | -330.07 m CNY |
| EBIT | -239.54 m CNY | -315.79 m CNY |
| Net income | -240.20 m CNY | -316.87 m CNY |
| Diluted EPS – continuing operations | -0.42 CNY | -0.55 CNY |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About InventisBio Co. Ltd. A
InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China. Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer; Taragarestrant (D-0502), which is in phase III and II to treat estrogen receptor positive/human epidermal growth factor receptor 2-breast cancer. The company also develops D"2570, which is in phase III, II, and I clinical trials, as well as preclinical trials to treat autoimmune disease; and Darbinurad (D-0120), which is in phase II clinical trial to treat gout. In addition, it is developing YF087 which is in preclinical trial to treat MSI-high solid tumors; YF550 which is in preclinical trial to treat chromosome instability solid tumors; and YF057 which is in preclinical trial to treat atopic dermatitis and asthma. InventisBio Co., Limited was founded in 2013 and is based in Shanghai, China.
More stocks
- SpyGlass Pharma, Inc. (SGP)
- Parksystems Corp (140860.KQ)
- BKS Bank AG (BKS.VI)
- Everest Medicines Ltd (1952.HK)
- China Bester Group Telecom Co Ltd (603220.SS)
- Fusheng Precision Co Ltd (6670.TW)
- BrightView Holdings, Inc. (BV)
- Jiangsu Zeyu Intelligent Power Co.Ltd. (301179.SZ)
- Renew Holdings PLC (RNWH.L)
- Nagarro (NA9.DE)
- Yuanta Futures Co Ltd (6023.TWO)
- JHSF Participações S.A. (JHSF3.SA)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.